ArticleHNO2011
[Immunotherapy of head and neck cancer. Identification of a novel mechanism for anti-EGFR mAb anti-tumor effects].
Article in HNO, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 3 citations in OpenAlex.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epidermal growth factor receptor (EGFR) is found to be overexpressed in nearly all squamous cell carcinomas of the head and neck (SCCHN). Monoclonal antibodies (mAbs) against EGFR are currently used to treat recurrent or metastatic disease; however, their mode of action is not fully understood. To investigate the immunological effects of anti-EGFR mAb, a three-dimensional spheroid model of EGFR-expressing SCCHN was generated and used to study the effect of anti-EGFR mAb on leukocyte migration towards tumors. The blockade of EGFR by anti-EGFR mAb in EGFR-overexpressing SCCHN cells led to differential expression (array) of several cytokines and chemokines, including the chemokine MCP-1/CCL-2. This was confirmed by quantitative PCR and ELISPOT analyses and shown to be functionally relevant by blocking experiments. These findings demonstrate that anti-EGFR mAb induces leukocyte infiltration to tumor spheroids by up-regulating chemokine expression. This novel mechanism for anti-EGFR mAb action may contribute to the anti-tumor effects of anti-EGFR mAb in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.